Voluntary Faculty
Voluntary faculty are typically clinicians or others who are employed outside of the School but make significant contributions to department programs at the medical center or at affiliate institutions.
Voluntary rank detailsJulia Shi, MD, FACP
Associate Clinical ProfessorAbout
Copy Link
Biography
She has served as the Medical Director of primary care services at the APT Foundation in New Haven Connecticut since completion of her substance abuse fellowship in 1992. She was involved with the initial clinical trial phase of buprenorphine in the early 1990s and established outpatient detoxification protocols for opioid users. She continues to participate in numerous NIH sponsored research projects in substance abuse – clinical investigator for the Psychotherapy Development Center and Yale Behavioral Pharmacology Laboratory. Her clinical role focuses on improving the treatment and care of patients with addiction and its associated comorbidities at the Central Medical Unit. This clinic is a national model delivering outpatient primary care within an addiction treatment center which offers methadone and buprenorphine for opioid use disorder treatment, outpatient detoxification in addition to general primary care.
She provides outpatient educational experiences to a wide variety of trainees, including medical students, internal medicine residents, and psychiatry and addiction fellows at the APT Foundation. She is part of the core faculty in the Program in Addiction Medicine and the ACGME accredited Addiction Medicine Fellowship, housed within the GIM section.
She has received national award for her outstanding contributions for opioid treatment and Yale award for her teaching for medical students.
Last Updated on May 30, 2024.
Appointments
General Internal Medicine
Associate Clinical ProfessorPrimary
Other Departments & Organizations
- Addiction Medicine Fellowship Program
- General Internal Medicine
- Internal Medicine
- Psychotherapy Development Center
Education & Training
- Internal Medicine Residency
- St Francis Hospital Medical Center (1992)
- MD
- SUNY at Syracuse (1987)
- BSc
- Cornell University, Chemical Engineering (1983)
Research
Copy Link
Research at a Glance
Yale Co-Authors
Frequent collaborators of Julia Shi's published research.
Publications Timeline
A big-picture view of Julia Shi's research output by year.
Jeanette Tetrault, MD, FACP, FASAM
Sherry McKee, PhD
Charla Nich
Samuel Ball, PhD
Patrick G. O'Connor, MD, MPH, MACP
Suchitra Krishnan-Sarin, PhD
33Publications
2,489Citations
Publications
2022
Primary Care Associated With Follow Up Viral Load Testing in Patients Cured of Hepatitis C Infection With Direct Acting Antivirals at a Multidisciplinary Addiction Treatment Program: Insights From a Real-World Setting
Haque LY, Butner JL, Shi JM, Henry S, Deng Y, Ciarleglio MM, Madden LM, Tetrault JM. Primary Care Associated With Follow Up Viral Load Testing in Patients Cured of Hepatitis C Infection With Direct Acting Antivirals at a Multidisciplinary Addiction Treatment Program: Insights From a Real-World Setting. Journal Of Addiction Medicine 2022, 16: 333-339. PMID: 34483278, PMCID: PMC9033626, DOI: 10.1097/adm.0000000000000910.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsHepatitis C virus infectionUrine toxicology resultsDirect acting antiviralsViral load testingSubstance use disordersAddiction treatment programsHCV reinfectionActing antiviralsToxicology resultsUse disordersDirect acting antiviral therapyTreatment programReal-world clinical settingHCV reinfection ratesActing antiviral (DAA) therapyC virus infectionHepatitis C infectionMedical service useCohort of patientsPrimary medical careSubstance use statusAddiction treatment settingsQuality improvement initiativesHCV cureC infectionChapter 9 Addiction management in the outpatient setting
Shi J, Slocum B, Tetrault J, Yanagisawa K. Chapter 9 Addiction management in the outpatient setting. 2022, 169-187. DOI: 10.1016/b978-0-323-79016-1.00008-8.ChaptersConceptsOpioid use disorderNonmedical opioid useOpioid useUntreated opioid use disorderPain management strategiesCurrent treatment optionsOpioid overdose crisisPostoperative painOutpatient settingTreatment optionsRisk factorsGeneral practitionersHigh riskEarly deathUse disordersAddiction specialistsCurrent opioid overdose crisisMedical providersBrain physiologyInfectious diseasesAddiction managementOverdose crisisAffected individualsDisordersThoughtful approach
2021
Saracatinib Fails to Reduce Alcohol-Seeking and Consumption in Mice and Human Participants
Thompson SL, Gianessi CA, O'Malley SS, Cavallo DA, Shi JM, Tetrault JM, DeMartini KS, Gueorguieva R, Pittman B, Krystal JH, Taylor JR, Krishnan-Sarin S. Saracatinib Fails to Reduce Alcohol-Seeking and Consumption in Mice and Human Participants. Frontiers In Psychiatry 2021, 12: 709559. PMID: 34531767, PMCID: PMC8438169, DOI: 10.3389/fpsyt.2021.709559.Peer-Reviewed Original ResearchCitationsAltmetricConceptsNMDA receptorsSrc/FynAlcohol consumptionEffect of saracatinibVehicle 2 hChronic alcohol useDays of treatmentDSM-IV criteriaMore effective treatmentsNumber of drinksGlutamatergic systemAdditional drinkAlcohol drinkingAdditional dosesEthanol exposureEffective treatmentNR2B subunitAlcohol abuseHuman studiesPriming drinkAlcohol cravingSaracatinibDrinking paradigmNovel pharmacotherapeuticsHuman participants
2019
Galantamine to reduce relapse after agonist taper for individuals with opioid use disorder
Sofuoglu M, Shi JM, Carroll KM. Galantamine to reduce relapse after agonist taper for individuals with opioid use disorder. Drug And Alcohol Dependence 2019, 203: 98. PMID: 31421476, DOI: 10.1016/j.drugalcdep.2019.05.013.Peer-Reviewed Original ResearchCitationsThe Kappa Opioid Receptor Is Associated With Naltrexone-Induced Reduction of Drinking and Craving
de Laat B, Goldberg A, Shi J, Tetrault JM, Nabulsi N, Zheng MQ, Najafzadeh S, Gao H, Kapinos M, Ropchan J, O'Malley SS, Huang Y, Morris ED, Krishnan-Sarin S. The Kappa Opioid Receptor Is Associated With Naltrexone-Induced Reduction of Drinking and Craving. Biological Psychiatry 2019, 86: 864-871. PMID: 31399255, DOI: 10.1016/j.biopsych.2019.05.021.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsKappa-opioid receptorsAlcohol use disorderOpioid receptorsUse disordersNonselective opioid receptor antagonistModest clinical effectsEfficacy of naltrexoneOpioid receptor antagonistDSM-IV criteriaPositron emission tomographyAlcohol Urge QuestionnaireNaltrexone initiationNaltrexone therapyClinical effectsReceptor antagonistTherapeutic effectCingulate cortexDrinking paradigmHeavy drinkersBilateral insulaNaltrexoneAlcohol dependenceBrain regionsEmission tomographyPrefrontal cortexRandomized Pilot Trial of Web-Based Cognitive-Behavioral Therapy Adapted for use in Office-Based Buprenorphine Maintenance
Shi JM, Henry SP, Dwy SL, Orazietti SA, Carroll KM. Randomized Pilot Trial of Web-Based Cognitive-Behavioral Therapy Adapted for use in Office-Based Buprenorphine Maintenance. Substance Abuse 2019, 40: 132-135. PMID: 30714880, PMCID: PMC6874094, DOI: 10.1080/08897077.2019.1569192.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsOffice-based buprenorphineOpioid use disorderBuprenorphine treatmentWeb-based interventionBuprenorphine maintenancePilot trialUse disordersBehavioral careCurrent opioid use disorderOffice-based buprenorphine treatmentUrine toxicology screenSpecific patient populationsDays of treatmentDSM-5 criteriaCognitive behavioral therapyInitial pilot testingToxicology screenPatient populationTwelve-weekEffective treatmentBuprenorphineDrug useSmall sample sizeTrialsPromising findings
2018
Effects of Varenicline Alone and in Combination With Low-dose Naltrexone on Alcohol-primed Smoking in Heavy-drinking Tobacco Users
Roberts W, Shi JM, Tetrault JM, McKee SA. Effects of Varenicline Alone and in Combination With Low-dose Naltrexone on Alcohol-primed Smoking in Heavy-drinking Tobacco Users. Journal Of Addiction Medicine 2018, 12: 227-233. PMID: 29438157, PMCID: PMC5970035, DOI: 10.1097/adm.0000000000000392.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsLow-dose naltrexoneTobacco usersTreatment outcomesPlacebo-controlled human laboratory studySmoking cessation treatmentEffects of vareniclineCigarettes ad libitumHuman laboratory studiesSubjective drug effectsVarenicline monotherapyCessation medicationsMedication therapyCessation treatmentMedication armTobacco useVareniclineLow doseSmoking relapseSmokingDrug effectsSmoking outcomesSmoking behaviorNaltrexoneCarbon monoxide levelsHeavy drinkersPilot investigation of the effect of carvedilol on stress-precipitated smoking-lapse behavior
Verplaetse TL, Weinberger AH, Ashare RL, Pittman BP, Shi JM, Tetrault JM, Lavery M, McKee SA. Pilot investigation of the effect of carvedilol on stress-precipitated smoking-lapse behavior. Journal Of Psychopharmacology 2018, 32: 1003-1009. PMID: 29692206, PMCID: PMC6258014, DOI: 10.1177/0269881118767647.Peer-Reviewed Original ResearchCitationsMeSH Keywords and ConceptsConceptsEffects of carvedilolSmoking lapse behaviorAdrenergic antagonistsTobacco cravingSmoking outcomesPhysiologic reactivitySystolic blood pressureNumber of cigarettesNicotine-motivated behaviors× time effectSelf-administration periodEffects of α1Human laboratory modelNicotine-deprived smokersPlacebo groupBlood pressureAdrenergic antagonismMedication conditionClinical indicationsNoradrenergic systemSubsequent smokingHeart rateProperties of drugsSmokingCarvedilolAn investigation of an open‐access model for scaling up methadone maintenance treatment
Madden LM, Farnum SO, Eggert KF, Quanbeck AR, Freeman RM, Ball SA, Schottenfeld RS, Shi JM, Savage ME, Barry DT. An investigation of an open‐access model for scaling up methadone maintenance treatment. Addiction 2018, 113: 1450-1458. PMID: 29453891, DOI: 10.1111/add.14198.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsNon-medical opioid useOpioid use disorderMethadone maintenance treatmentOpioid useMaintenance treatmentTreatment accessUse disordersTreatment modelMethadone maintenance treatment centersMaintenance treatment centersDeleterious effectsMethadone treatmentPatient mortalityTreatment optionsTreatment outcomesTreatment centersProspective patientsRate of retentionPatient censusRapid enrollmentAddiction treatmentApparent deleterious effectsTreatmentMortalityProgrammatic outcomesGalantamine and Computerized Cognitive Behavioral Therapy for Cocaine Dependence: A Randomized Clinical Trial.
Carroll KM, Nich C, DeVito EE, Shi JM, Sofuoglu M. Galantamine and Computerized Cognitive Behavioral Therapy for Cocaine Dependence: A Randomized Clinical Trial. The Journal Of Clinical Psychiatry 2018, 79: 17m11669. PMID: 29286595, PMCID: PMC5866530, DOI: 10.4088/jcp.17m11669.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsComputerized cognitive behavioral therapyStandard methadone treatmentCocaine use outcomesBenefits of galantamineMethadone treatmentCognitive behavioral therapyCognitive functionUse outcomesCommunity-based methadone maintenance programCocaine useStandard methadone maintenance treatmentBehavioral therapyUrine toxicology screenMethadone maintenance treatmentMethadone maintenance programCocaine treatment outcomesNicotinic acetylcholine receptorsCognitive functioningCocaine use disorderMethadone dosingSecondary outcomesToxicology screenMaintenance treatmentClinical trialsMedication administration
Academic Achievements & Community Involvement
Copy Link
Honors
honor The Annual Department Award for Excellence in Teaching Ambulatory Care Internal Medicine to Medical Students
09/02/2008Yale School of Medicine AwardYale University, Department of Internal MedicineDetailsUnited Stateshonor The Nyswander/Dole Award
10/23/2007National AwardAmerican Association for Treatment of Opioid DependenceDetailsUnited States
News
Copy Link
Get In Touch
Copy Link
Contacts
Email